The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
PD Subtypes, 2007Longitudinal changes in patterns of motor UPDRS subscore
Tremor, bradykinesia (slowness of movement), rigidity (stiffness) and walking/balance impairment are the major signs of Parkinson's disease; a middle-age onset with slow progression is archetypal...
-
PD Subtypes, 2007Prediction of Death, Dementia, Disability, Depression from the Time Course of UPDRS Motor Status
Parkinson’s disease is progressive. Early on, its effects are relatively minor, affecting mainly movement and causing shaking of the limbs. Later on, serious events -- early death, dementia...
-
PD Subtypes, 2007Defining PD Subtypes Based on Patterns of Long-term Outcome
The purpose of our study is to identify Parkinson’s disease subtypes based on how individuals are doing approximately seven to eight years after diagnosis. Some patients have few symptoms at this time...
-
Target Validation, 2007Functional Inhibition of RasGRF1 in the MPTP-lesioned NHP Model for Treating Levodopa-induced Dyskinesia
Objective/Rationale:
Levodopa-induced dyskinesias are caused by an increased and aberrant response of dopamine receptors to dopamine in the striatum. Among other intracellular pathways, the MAP kinase... -
Target Validation, 2007Validation of metabotropic glutamate-receptor type 5 as a target for the treatment of L-DOPA-induced dyskinesia in a macaque model of Parkinson´s disease
Objective/Rationale:
Metabotropic glutamate receptor type 5 (mGluR5) is abundantly expressed in striatal neurons, where it modulates the response to glutamatergic and dopaminergic inputs. Previous... -
Target Validation, 2007Inhibition of c-Abl Tyrosine Kinase as a Novel Therapy to Prevent PD ProgressionObjective/Rationale: Mutations in the parkin gene cause early-onset autosomal recessive PD. We have discovered that parkin is modified by an oxidative-stress induced signaling kinase, c...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.